A Delaware judge dismissed a former Aurion Biotech executive’s challenge to a stockholder’s alleged takeover of the company, finding he failed to plausibly allege that defendants caused the abandonment of the planned IPO.
A Delaware judge dismissed a former Aurion Biotech executive’s challenge to a stockholder’s alleged takeover of the company, finding he failed to plausibly allege that defendants caused the abandonment of the planned IPO.
